Clinical Significance of HER2-low Breast Cancer

被引：0
|
作者：
Zaiem, Fadi
AbuJamea, Asem
Kheil, Mira
Numi, Anna
Abbas, Omar
Awada, Sanaa
Almsaddi, Ragad
Al-Juburi, Saleh
Larson, Lauren
Jain, Deepti
AlSaghir, Maya
Jang, Hyejeong
Kim, Seongho
Bandyopadhyay, Sudeshna
Jaiman, Sunil
Ali-Fehmi, Rouba
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-01-11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-01-11
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Clinical and Epidemiologic Significance of HER2-Low Expression in Breast Cancer in the Pathways Study
    Khoury, Thaer
    Ondracek, Rochelle Payne
    Yao, Song
    Mendocino, Lucas
    Davis, Warren
    Omilian, Angela
    Kwan, Marilyn
    Roh, Janise
    D'Addario, Lia
    Valice, Emily
    Fernandez, Daniel
    Ergas, Isaac
    Ambrosone, Christine
    Kushi, Lawrence
    CANCER RESEARCH, 2024, 84 (09)
  • [2] HER2-Low Breast Cancer: Pathological and Clinical Landscape
    Tarantino, Paolo
    Hamilton, Erika
    Tolaney, Sara M.
    Cortes, Javier
    Morganti, Stefania
    Ferraro, Emanuela
    Marra, Antonio
    Viale, Giulia
    Trapani, Dario
    Cardoso, Fatima
    Penault-Llorca, Frederique
    Viale, Giuseppe
    Andre, Fabrice
    Curigliano, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (17) : 1951 - +
  • [3] HER2-low breast cancer: A new clinical entity
    Rashid, Yasmin Abdul
    Khan, Samra
    Khan, Shagufta
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2025, 75 (01) : 149 - 150
  • [4] Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer
    Shang, Jiuyan
    Sun, Xuemei
    Xu, Zihang
    Cai, Lijing
    Liu, Chang
    Wu, Si
    Liu, Yueping
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [5] The clinicopathological and prognostic significance of HER2-low breast cancer: A comparative analysis between HER2-low and HER2-zero subtypes
    Nishimura, Reiki
    Fujiki, Yoshitaka
    Taira, Tetsuhiko
    Miyaki, Toshiko
    Kanemitsu, Shuichi
    Yotsumoto, Daisuke
    Teraoka, Megumi
    Kawano, Junko
    Gondo, Naomi
    Mitsueda, Reiko
    Baba, Shinichi
    Ohi, Yasuyo
    Rai, Yoshiaki
    Sagara, Yoshiaki
    Sagara, Yasuaki
    CANCER RESEARCH, 2024, 84 (09)
  • [6] The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes
    Nishimura, Reiki
    Fujiki, Yoshitaka
    Taira, Tetsuhiko
    Miyaki, Toshiko
    Kanemitsu, Shuichi
    Yotsumoto, Daisuke
    Teraoka, Megumi
    Kawano, Junko
    Gondo, Naomi
    Mitsueda, Reiko
    Baba, Shinichi
    Ohi, Yasuyo
    Rai, Yoshiaki
    Sagara, Yoshiaki
    Sagara, Yasuaki
    CLINICAL BREAST CANCER, 2024, 24 (05) : 431 - 438
  • [7] Clinical and Biological Significance of HER2-Low in Ductal Carcinoma In Situ of the Breast
    Ciniselli, Chiara M.
    Verderio, Paolo
    Baili, Paolo
    Sant, Milena
    Pizzamiglio, Sara
    Duroni, Valeria
    de Braud, Filippo G.
    Folli, Secondo
    Scaperrotta, Gianfranco
    De Santis, Maria C.
    Apolone, Giovanni
    De Marco, Cinzia
    Vingiani, Andrea
    Cappelletti, Vera
    Pruneri, Giancarlo
    Di Cosimo, Serena
    CLINICAL BREAST CANCER, 2025, 25 (01)
  • [8] Characteristics and clinical outcomes of patients with HER2-low breast cancer
    Koh, S.
    Koi, Y.
    Tajiri, W.
    Kawasaki, J.
    Akiyoshi, S.
    Nakamura, Y.
    Koga, C.
    Tokunaga, E.
    BREAST, 2023, 68 : S32 - S32
  • [9] Prognostic and biologic significance of HER2-low expression in early breast cancer
    Tarantino, P.
    Jin, Q.
    Tayob, N.
    Jeselsohn, R.
    Schnitt, S. J.
    Vincuilla, J.
    Parker, T.
    Tyekucheva, S.
    Lin, N. U.
    Hughes, M.
    Weiss, A. C.
    King, T. A.
    Mittendorf, E. A.
    Curigliano, G.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2022, 33 : S124 - S124
  • [10] Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
    Huang, C-C.
    Chen, G.
    Tseng, L-M.
    Chen, B-F.
    ANNALS OF ONCOLOGY, 2023, 34 : S1476 - S1476
12345